|
|
HIV Update 2002 (1) - JanuaryPublished by: Datamonitor Published: Feb. 12, 2002 - 25 Pages Table of ContentsDATAMONITOR HEALTHCARE CONTACT DETAILS EXECUTIVE SUMMARY Datamonitor insight into the HIV Market CHAPTER 1 INTRODUCTION Impact of Side Effects Associated with Anti-retroviral Therapy Focus on the Future of HIV Therapeutics and Prophylactics Mode of HIV Transmission Could Impact Treatment Strategies and Drug Sales CHAPTER 2 ANALYSIS OF KEY DEVELOPMENTS IN JANUARY 2002 COMPANY HEADLINES Screening Test Developed for Allergic Reactions to GSK’s Ziagen Coviracil Development Favoured over Coactinon Immune Network and University of British Columbia Join Forces on HIV Collaboration RESEARCH AND DEVELOPMENT HEADLINES Renewed Hopes for AIDSVAX Following New Trial Data DISEASE SPECIFIC HEADLINES Research Focuses on HIV-Positive Women US and UK Sets Up Initiatives to Monitor HIV Epidemiology and Treatment Outcomes Upregulation of CCR5 in Methadone Treated Heroin Addicts Potential Tool to Assess Risk of Disease Progression in HAART-Treated HIV Patients Research Questions Benefits of Addition of IL-2 to HAART Therapy EMERGING MARKETS HEADLINES Increased Education in Ethiopia May Greaten the Risk of HIV Transmission South Africa’s KwaZulu Natal Province Accepts BI’s Viramune Donation CHAPTER 6 APPENDIX Datamonitor's Infectious Disease Business Unit Contacts and Further Reading © Datamonitor 2002. All Rights Reserved. AbstractThis HIV monthly update provides an analysis of key HIV and AIDS market events that have occurred during January 2002. Both commercial and clinical events are covered, thereby providing a concise, yet thorough overview of the events that have impacted the HIV market in this month.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||